| Literature DB >> 31406344 |
Olaf Hiort1, Martine Cools2,3, Alexander Springer4, Ken McElreavey5, Andy Greenfield6, Stefan A Wudy7, Alexandra Kulle8, S Faisal Ahmed9, Arianne Dessens10, Antonio Balsamo11, Mohamad Maghnie12, Marco Bonomi13,14, Mehul Dattani15, Luca Persani13,14, Laura Audi16.
Abstract
Differences of sex development are conditions with discrepancies between chromosomal, gonadal and phenotypic sex. In congenital hypogonadotropic hypogonadism, a lack of gonadotropin activity results primarily in the absence of pubertal development with prenatal sex development being (almost) unaffected in most patients. To expedite progress in the care of people affected by differences of sex development and congenital hypogonadotropic hypogonadism, the European Union has funded a number of scientific networks. Two Actions of the Cooperation of Science and Technology (COST) programmes - DSDnet (BM1303) and GnRH Network (BM1105) - provided the framework for ground-breaking research and allowed the development of position papers on diagnostic procedures and special laboratory analyses as well as clinical management. Both Actions developed educational programmes to increase expertise and promote interest in this area of science and medicine. In this Perspective article, we discuss the success of the COST Actions DSDnet and GnRH Network and the European Reference Network for Rare Endocrine Conditions (Endo-ERN), and provide recommendations for future research.Entities:
Mesh:
Year: 2019 PMID: 31406344 DOI: 10.1038/s41574-019-0238-y
Source DB: PubMed Journal: Nat Rev Endocrinol ISSN: 1759-5029 Impact factor: 43.330